{
    "clinical_study": {
        "@rank": "50378", 
        "arm_group": [
            {
                "arm_group_label": "Patients with spinal muscular atrophy"
            }, 
            {
                "arm_group_label": "Age- and gender-matched controls"
            }
        ], 
        "biospec_descr": {
            "textblock": "Whole blood samples taken at screening and at week 24 from patients with spinal muscular\n      atrophy (SMA)."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This non-drug, single center, 24-week, longitudinal study in ambulant spinal muscular\n      atrophy (SMA) patients and in age- and gender-matched healthy volunteers will assess the\n      detection of disease progression by magnetic resonance imaging (MRI) and the Muscle Function\n      Measure (MFM) test.\n\n      Each participant will be evaluated in three testing sessions: at baseline, at Week 12 and at\n      Week 24. Both patients and volunteers will undergo MRI scans. Patients will additionally\n      undergo testing of motor function and have blood samples taken for Survival of the Motor\n      Neuron (SMN) genes, proteins and mRNA analysis."
        }, 
        "brief_title": "Ability of Muscle Imaging and Motor Function Measure (MFM) to Detect Changes in Disease Progression in Ambulant Spinal Muscular Atrophy Patients Compared to Healthy Volunteers.", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer, Muscular Atrophy, Spinal", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Atrophy", 
                "Muscular Atrophy, Spinal", 
                "Disease Progression", 
                "Atrophy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects, aged >/= 10 years at screening\n\n          -  For SMA patients: Confirmed clinical diagnosis of 5q-autosomal recessive SMA,\n             ambulant at time of screening, and prefereably without spinal cord fixation\n\n        Exclusion Criteria:\n\n          -  Previous (3 months or less) or concomitant participation in any other therapeutic\n             trial\n\n          -  Known or suspected cancer\n\n          -  Other chronic disease or inadequate renal, liver, or heart function\n\n          -  Contraindications for MRI scans, including but not limited to: claustrophobia,\n             pacemaker, artifical heart valves, cochlear implants, presence of foreign metal\n             objects in the body, intracranial vascular clips, etc. Any contraindications to MRI\n             found on a standard radiography scan."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "10 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Ambulant patients with spinal muscular atrophy (SMA) and age- and gender-matched healthy\n        volunteers."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044029", 
            "org_study_id": "BE29037"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "number_of_groups": "2", 
        "official_title": "A SINGLE CENTER, LONGITUDINAL, NON-DRUG STUDY TO ASSESS THE ABILITY OF MUSCLE IMAGING AND OF MOTOR FUNCTION MEASURE (MFM) TO DETECT CHANGES IN DISEASE PROGRESSION IN AMBULANT SPINAL MUSCULAR ATROPHY (SMA) PATIENTS AS COMPARED TO AGE-MATCHED HEALTHY CONTROLS", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: BE29037 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "N/A: N/A"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Differences in quantitative muscle MRI based on fat content and T2 values", 
                "safety_issue": "No", 
                "time_frame": "At baseline, Week 12 and Week 24"
            }, 
            {
                "measure": "Disease progression, assessed through the Motor Function Measure test", 
                "safety_issue": "No", 
                "time_frame": "At baseline, Week 12 and Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044029"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease progression, assessed with the 6-minute Walk Test.", 
                "safety_issue": "No", 
                "time_frame": "At baseline, Week 12 and Week 24"
            }, 
            {
                "measure": "Levels of Survival of Motor Neuron (SMN) RNA", 
                "safety_issue": "No", 
                "time_frame": "At baseline and Week 24"
            }, 
            {
                "measure": "Levels of SMN proteins", 
                "safety_issue": "No", 
                "time_frame": "At baseline and Week 24"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}